United Therapeutics (UTHR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$506.82+1.78%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Deliver durable double-digit revenue growth: rev -2.0% vs 11% target.
United Therapeutics grows revenue about 11% a year. It keeps profit margins near recent levels despite cost pressures. The company benefits from new FDA approvals and strong product franchises. It also returns cash via a $2 billion buyback program.
Revenue growth is slowing with a recent 2% decline year-over-year. Profit fell 15% below expectations last quarter. Operating income is declining, showing cost control challenges. New product launches may not offset these headwinds.
The market prices in about 11% revenue growth and values the stock slightly above our fair value near $537. Our fair value is below the Street median, reflecting caution on margin and growth sustainability.
Breaks if: Buyback program is suspended or materially reduced
Breaks if: Operating income falls below $300M next 4 quarters
No major product approvals or launches in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on advancing regulatory approvals and sustaining commercial performance. The current thesis state is stable, supported by recent strong financial results despite some industry challenges.
The market currently prices UTHR as cheap compared to its peers, reflecting a negative expectations gap. There is a low level of fragility in the stock, indicating that investors do not expect significant volatility in the near term.
Fundamentals are likely to remain strong as management executes on key priorities, including advancing regulatory approvals and sustaining Tyvaso DPI's commercial performance. However, there is a moderate risk due to potential economic downturns affecting the healthcare sector.
The thesis hinges on management's ability to deliver on regulatory approvals and maintain growth in Tyvaso DPI revenues. Additionally, the performance of sector bellwethers and broader economic indicators will influence UTHR's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. FDA approvals for ralinepag and Tyvaso are advancing regulatory progress. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 6% in FY26
Overall, UTHR appears well-positioned for the next few years, supported by solid management and a strong product pipeline. Not investment advice.